Gamma Knife Market (2023 - 2030)

Gamma Knife Market Size & Trends

The global gamma knife market size was valued at USD 424.7 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.0% from 2023 to 2030. Increasing prevalence of neurological disorders & brain tumors, rapid adoption of gamma knife surgeries as an effective treatment option, continuous technological advancements, and evolution of minimally invasive surgery options are expected to fuel the market. However, higher costs of treatments & installation of machinery, fluctuating reimbursement rates, and dearth of skilled professionals are factors expected to hamper market growth.

The COVID-19 pandemic has negatively impacted radiology practices across the globe. A 50.0% reduction in elective surgeries was witnessed within the first month of the pandemic. Hospitals are mainly focusing on tackling COVID-19 cases, which minimized their capacity to undertake critical radiotherapy operations. Reduction in raw material production, halt in logistics, reduced sales of newer systems, and national lockdowns were other reasons for the drop in market size in 2020.

The global burden of neurological disorders is measured by the absolute number of Disability-adjusted Life Years (DALYs), which continues to increase. The prevalence of major neurological disorders is increasing owing to rising geriatric population. According to American Cancer Society, brain tumor is considered as the 8th most common type of cancer and 3rd most common cause of cancer deaths in the age group of 40 & above. As population is aging and growing, the demand for treatment and rehabilitation for neurological diseases is expected to increase significantly, hence impacting the growth of the market.

Gamma knife surgery is a computer-guided treatment, which is painless and used to deliver strong focused radiation beams to treat brain tumors and lesions, arteriovenous malformations, acoustic neuroma, tremors, and trigeminal neuralgia. For instance, Leksell Gamma Knife Icon, by key market player Elekta AB (publ), uses single or fractionated frame-based or frameless treatments with more precision and accuracy for brain tumors, cancer, and other neurological diseases.

Product Insights

Based on indication, the market is segmented into malignant tumors, benign tumors, vascular disorders, functional disorders, and ocular brain tumors. The malignant tumors segment held the largest share in 2022 capturing 45.7% of the global industry. The benign tumors segment is expected to grow at the fastest rate over the forecast period, owing to increasing prevalence of meningioma.

According to American Society of Clinical Oncology (ASCO), currently, 700,000 patients are suffering from brain tumors. In 2021, around 24,530 adults-13,840 males and 10,690 females-in the U.S. are expected to be diagnosed with the primary type of malignant tumor in the spinal cord and brain. In addition, around 3,460 children under the age of 15 years are expected to be diagnosed with brain tumors. Around 18,600 adults-around 10,500 males and 8,100 females-are likely to die due to these types of cancer in the coming year, thereby augmenting the segment’s growth.

Regional Insights

In 2022, Asia Pacific held the largest market with over 38.0% share. Increase in prevalence of neurological diseases, rise in healthcare expenditures, and growth in accessibility of gamma knife surgeries are some of the key factors expected to drive Asia Pacific’s gamma knife market over the forecast period.

Furthermore, the adoption of gamma knife surgery systems is reported to be increasing in North America. Moreover, various clinical studies are being undertaken for exploring the applications of gamma knife radiotherapy in treating essential tremors, such as Parkinson’s and glioblastoma. Thus, the expansion of applications of gamma knife radiotherapy to other treatment areas is expected to further drive the market.

Key Companies & Market Share Insights

Major participants in the market are involved in multiple strategic initiatives such as mergers & acquisitions, new product launch, collaborations and other initiatives. For instance, in May 2020, Elekta launched Leksell Gamma Knife Lightning, which was the only fully integrated automated treatment planning solution for gamma knives that enables plan-optimization based on parameters such as beam on-time constraints. Some prominent players in the global gamma knife market include:

• Elekta AB

• Varian Medical Systems

• Huiheng Medical, Inc.

• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.

• Akesis Inc.

Gamma Knife Market